CTOs on the Move

Flagship Biosciences

www.flagshipbio.com

 
Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data for improved drug development and diagnostics. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Aymii Couzelis
 Chief Information Officer Profile

Similar Companies

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evidence CPR

EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses

Sapphire Biotech

Sapphire Biotech, Inc.`s diagnostic tool is being used to study the company`s enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells.

Onconome

Onconome is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.